Magouliotis Dimitrios E, Asprodini Eftihia K, Svokos Konstantina A, Tasiopoulou Vasiliki S, Svokos Alexis A, Toms Steven A
Department of Surgery, University Hospital of Larissa, Larissa, Greece.
Laboratory of Pharmacology, School of Medicine, University of Thessaly, Larissa, Greece.
Acta Neurochir (Wien). 2018 Jun;160(6):1167-1174. doi: 10.1007/s00701-018-3536-6. Epub 2018 Apr 25.
We aim to review the available literature on patients suffering from glioblastoma treated with tumor-treating fields (TTFields) plus radio chemotherapy or conventional radio chemotherapy alone, to compare the efficacy and safety of the two methods.
A systematic literature search was performed in PubMed, Cochrane library, and Scopus databases, in accordance with the PRISMA guidelines. Six studies met the inclusion criteria incorporating 1806 patients for the qualitative analysis and 1769 for the quantitative analysis.
This study reveals increased median overall survival (weighted mean difference (WMD) 3.29 [95% confidence interval (CI) 2.37, 4.21]; p < 0.00001), survival at 1 year (odds ratio (OR) 1.81 [95% CI 1.41, 2.32]; p < 0.00001) and 2 years (OR 2.33 [95% CI 1.73, 3.14]; p < 0.00001), and median progression-free survival (WMD 2.35 [95% CI 1.76, 2.93]; p < 0.00001) along with progression-free survival at 6 months (WMD 6.86 [95% CI 5.91, 7.81]; p < 0.00001) for the patients treated with TTFields. Survival at 3 years was comparable between the two groups. TTFields were associated with fewer adverse events compared to chemotherapy along with similar incidence of skin irritation.
TTFields are a safe and efficient novel treatment modality. More randomized controlled studies, with longer follow-up, are necessary to further assess the clinical outcomes of TTFields.
我们旨在回顾关于胶质母细胞瘤患者接受肿瘤治疗电场（TTFields）联合放化疗或单纯传统放化疗的现有文献，以比较两种方法的疗效和安全性。
根据PRISMA指南，在PubMed、Cochrane图书馆和Scopus数据库中进行系统的文献检索。六项研究符合纳入标准，纳入1806例患者进行定性分析，1769例进行定量分析。
本研究显示，接受TTFields治疗的患者中位总生存期延长（加权平均差（WMD）3.29 [95%置信区间（CI）2.37, 4.21]；p < 0.00001），1年生存率（优势比（OR）1.81 [95% CI 1.41, 2.32]；p < 0.00001）和2年生存率（OR 2.33 [95% CI 1.73, 3.14]；p < 0.00001），以及中位无进展生存期（WMD 2.35 [95% CI 1.76, 2.93]；p < 0.00001）和6个月无进展生存期（WMD 6.86 [95% CI 5.91, 7.81]；p < 0.00001）。两组3年生存率相当。与化疗相比，TTFields相关的不良事件更少，皮肤刺激发生率相似。
TTFields是一种安全有效的新型治疗方式。需要更多随访时间更长的随机对照研究来进一步评估TTFields的临床疗效。
